Volume 132, Issue 7



August 16, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Increased risk of lymphoma following the use of JAK inhibitors. See the article by Porpaczy et al.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Porpaczy et al report an increased frequency of aggressive lymphomas in a cohort of patients following JAK1/2 inhibitor treatment for myelofibrosis.

Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia
Dia et al describe findings that further understanding of how cell surface-bound platelet factor 4 (PF4) distributes itself on various blood cells and endothelium under normal and experimental conditions. Their findings also add to our understanding of the pathophysiology of heparin-induced thrombocytopenia.

Novel agents for primary central nervous system lymphoma: evidence and perspectives
In their Perspective, Illerhaus et al discuss the latest insights in the pathophysiology of primary central nervous system lymphoma and present an overview of the use of novel agents in this disease.

L-Glutamine for sickle cell anemia: more questions than answers
This Blood Spotlight provides a comprehensive summary of the preclinical biochemical studies and the clinical development of L-Glutamine, including the recent clinical trials in sickle cell disease that led to its approval by the Food and Drug Administration.

Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia
The inability to provide transfusion support to patients with leukemia is a major cause of hospice enrollment delays for end-of-life care. This study explores the relationship between transfusion dependence, time to hospice enrollment, and quality of end-of-life care in patients with leukemia.

Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study
Historically, the therapeutic outcome of allogeneic transplantation with alternative donors for severe aplastic anemia has been disappointing. This month’s CME article presents a large prospective study using an adjusted conditioning platform showing reproducible engraftment and excellent survival.

Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations
Rutherford et al present novel insights into the biology of lymphoma. They examine exosomes and their RNA content in diffuse large B-cell lymphoma (DLBCL) and elucidate the impact of transfer of DLBCL-derived exosomes on the transcriptional reprogramming and mutational profiles of recipient lymphoma cells.

Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment
Using highly sophisticated flow techniques, Kaur et al identify myeloablation-resistant resident macrophage subtypes in both the spleen and marrow of hematopoietic stem cell (HSC)–transplanted mice and demonstrate a crucial function for these macrophages in HSC engraftment.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
This article reports encouraging results of rituximab-bendamustine treatment in a retrospective series of 27 patients with immunoglobulin M (IgM)–associated light chain amyloidosis.

Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP)
In a multicenter study of over 3000 patients with cancer and an implanted catheter, Decousus et al identify risk factors for venous thrombosis.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.